We previously demonstrated that a deficiency of natural antibodies against CD25, Mucin 1 (MUC1), and vascular endothelial growth factor receptor 1 (VEGFR1) could contribute to high risk of non‐small cell lung cancer (NSCLC). This study was designed to investigate whether natural IgG antibodies against POU domain class 5 transcription factor 1 (POU5F1), tumor necrosis factor‐α (TNF‐α), and the combination of CD25, VEGFR1, and MUC1 could play an anti‐tumorigenic role against developing NSCLC. An ELISA was developed in‐house to examine plasma IgG against peptide antigens derived from POU5F1, TNF‐α, and a combination of peptide antigens derived from CD25, MUC1, and VEGFR1 in 211 patients with NSCLC and 200 healthy controls. Mann–Whitney U test demonstrated that plasma IgG levels for the combination of peptide antigens derived from CD25, MUC1, and VEGFR1 were significantly lower in NSCLC patients than control subjects (Z = −12.978, P < 0.001) although plasma levels of IgG antibodies for POU5F1 and TNFα were not significantly changed. The in‐house ELISA made with the CD25‐MUC1‐VEGFR1 combination had a sensitivity of 49.6% against a specificity of 95% to detect early‐stage NSCLC. In conclusion, natural antibodies against the combination of CD25, VEGFR1, and MUC1 may be an effective biomarker for early diagnosis of NSCLC.

中文翻译：

---

检测针对 CD25、MUC1 和 VEGFR1 的循环天然抗体，用于非小细胞肺癌的早期诊断。

我们之前已经证明，缺乏针对 CD25、粘蛋白 1 (MUC1) 和血管内皮生长因子受体 1 (VEGFR1) 的天然抗体可能导致非小细胞肺癌 (NSCLC) 的高风险。本研究旨在研究针对 POU 结构域 5 类转录因子 1 (POU5F1)、肿瘤坏死因子-α (TNF-α) 的天然 IgG 抗体以及 CD25、VEGFR1 和 MUC1 的组合是否可以发挥抗肿瘤作用反对发展中的非小细胞肺癌。内部开发了 ELISA，用于检测 211 名 NSCLC 患者和 200 名健康对照中针对 POU5F1、TNF-α 和 CD25、MUC1 和 VEGFR1 衍生的肽抗原组合的肽抗原的血浆 IgG。曼-惠特尼ü测试表明，NSCLC 患者中来自 CD25、MUC1 和 VEGFR1 的肽抗原组合的血浆 IgG 水平显着低于对照受试者（Z  = -12.978，P <  0.001），尽管 POU5F1 和 TNFα 的 IgG 抗体的血浆水平是没有显着变化。使用 CD25-MUC1-VEGFR1 组合进行的内部 ELISA 检测早期 NSCLC 的灵敏度为 49.6%，特异性为 95%。总之，针对CD25、VEGFR1和MUC1组合的天然抗体可能是NSCLC早期诊断的有效生物标志物。